甲异靛 化学药品说明书异甲靛片甲异靛片
Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines. Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia. Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest. Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells. Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells.
Cell Viability Assay
Apoptosis Analysis
Cell Cycle Analysis
Western Blot Analysis
Meisoindigo (Dian III; 50-150 mg/kg; IP; daily; for 14 days) has anti-leukemic activity in vivo. Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain.